On October 18, 2022 Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, reported it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, for a glypican 2 (GPC2) binding domain to be used for the potential development and commercialization of ARTEMIS T cell therapies for patients with neuroblastoma, a rare cancer that affects the developing nervous system (Press release, Eureka Therapeutics, OCT 18, 2022, View Source [SID1234622148]). The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neuroblastoma is a rare cancer that affects the development of the nervous system by attacking immature nerve cells as early as the embryonic stage. Each year, about 800 children are diagnosed with neuroblastoma in the U.S., and overall survival rates are lower than 50%. Current chemotherapy options for these patients are limited and highly toxic, which highlights the urgent need for new treatments for this disease to improve overall survival and reduce long-term toxicity.

"GPC2 is an exciting new target for neuroblastoma. In pre-clinical models, anti-GPC2 directed ARTEMIS T cells demonstrated significant tumor-killing activity," said Dr. Mitchell Ho, Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the NCI Center for Cancer Research. "We believe it is beneficial to further evaluate anti-GPC2 directed ARTEMIS T cells as a potential T cell therapy for patients with neuroblastoma and other cancers that express GPC2."

"The expansion of our pipeline with an anti-GPC2 program supports our effort to deliver the potential benefit of ARTEMIS T cell therapies for patients with neuroblastoma. As the field of T cell therapy continues its rapid advancement, we remain committed to pioneering the next generation of T cell therapies." said Dr. Cheng Liu, President and Chief Executive Officer of Eureka Therapeutics.

On October 18, 2022 Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, reported it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, for a glypican 2 (GPC2) binding domain to be used for the potential development and commercialization of ARTEMIS T cell therapies for patients with neuroblastoma, a rare cancer that affects the developing nervous system (Press release, Eureka Therapeutics, OCT 18, 2022, View Source [SID1234622148]). The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neuroblastoma is a rare cancer that affects the development of the nervous system by attacking immature nerve cells as early as the embryonic stage. Each year, about 800 children are diagnosed with neuroblastoma in the U.S., and overall survival rates are lower than 50%. Current chemotherapy options for these patients are limited and highly toxic, which highlights the urgent need for new treatments for this disease to improve overall survival and reduce long-term toxicity.

"GPC2 is an exciting new target for neuroblastoma. In pre-clinical models, anti-GPC2 directed ARTEMIS T cells demonstrated significant tumor-killing activity," said Dr. Mitchell Ho, Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the NCI Center for Cancer Research. "We believe it is beneficial to further evaluate anti-GPC2 directed ARTEMIS T cells as a potential T cell therapy for patients with neuroblastoma and other cancers that express GPC2."

"The expansion of our pipeline with an anti-GPC2 program supports our effort to deliver the potential benefit of ARTEMIS T cell therapies for patients with neuroblastoma. As the field of T cell therapy continues its rapid advancement, we remain committed to pioneering the next generation of T cell therapies." said Dr. Cheng Liu, President and Chief Executive Officer of Eureka Therapeutics.

On October 18, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will report its third quarter 2022 financial results after market close on November 8th, 2022 (Press release, Zymeworks, OCT 18, 2022, View Source [SID1234622147]). Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 8th, 2022 at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information

The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at View Source

On October 18, 2022 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, reported the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images (Press release, Blue Earth Diagnostics, OCT 18, 2022, View Source [SID1234622145]). Siemens Healthineers plans to evaluate the data to enhance its analytics and artificial intelligence (AI)-based algorithms for prostate cancer across its advanced PET/CT imaging software. 18F-rhPSMA-7.3 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent in development by Blue Earth Diagnostics for diagnostic imaging of newly diagnosed and biochemically recurrent prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Blue Earth Diagnostics is committed to helping men with prostate cancer across the care continuum, and we recognize the importance of AI in advancing healthcare," said David Gauden, D.Phil., Chief Executive Officer, Blue Earth Diagnostics. "AI-based algorithms have the potential to streamline the PET/CT analytical workflow for hospitals and imaging centers, by efficiently providing physicians with information critical to patient management and care, and freeing them to spend more time with patients. Blue Earth has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare. We are excited to collaborate on this project to facilitate provision of anonymized 18F-rhPSMA-7.3 data from TUM which will be used to enhance the analytical workflows for the Siemens Healthineers Biograph and syngo.via platforms. The project includes evaluation of diagnostic analytical techniques for 18F-rhPSMA-7.3 data as well as exploring their theranostic potential in radiopharmaceutical therapy. Looking forward, we also plan to make analytical data from Blue Earth Diagnostics’ Phase 3 clinical trials for 18F-rhPSMA-7.3 available, which includes robust histopathology data as the gold Standard of Truth."

The agreement covers use of anonymized 18F-rhPSMA-7.3 PET/CT data from TUM by Siemens Healthineers to evaluate workflow improvements for image acquisition and interpretation; dose optimization; detection of small metastases and recurrent tumors; evaluation of patients in earlier stages of disease progression and stratification by low PSA levels; and, together with histopathology, assessment of the sensitivity of results. The data will also be used to define and optimize 18F-rhPSMA-7.3 workflow prior to PSMA-targeted radioligand therapy in prostate cancer, to assess its theranostic potential in therapeutic dose planning and the likelihood of treatment success.

"The TUM experience with rhPSMA has allowed us to investigate the potential performance of a new class of theranostic PSMA-targeting agents that enable efficient labelling with radioisotopes such as 18F for PET imaging or 177Lu for therapeutic use," said Matthias Eiber, MD, PhD, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM. "We are happy that 18F-rhPSMA-7.3 PET/CT imaging scans performed at TUM as part of routine patient care in prostate cancer can be part of this project to inform AI-based algorithms for improved PET/CT workflows. The use of AI has the potential to markedly improve the quality of PET/CT as well as enhance the ability to interpret the scans and follow lesions over time. This will hopefully lead to expanded clinical use cases for this valuable technology, leading to better patient care."

"We are pleased to collaborate with Blue Earth Diagnostics and TUM on this data-sharing agreement for 18F-rhPSMA-7.3," said Bruce Spottiswoode, Director, Clinical Applications Research, Siemens Healthineers. "These data will help us optimize the acquisition and processing of 18F-based PSMA imaging and therapeutic radiopharmaceuticals across our family of PET/CT scanners and reading solutions."

About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)

rhPSMA compounds are referred to as radiohybrid ("rh"), as each molecule possesses three distinct domains. The first consists of a Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells. It is attached to two labelling moieties which may be radiolabeled with either 18F for PET imaging, or with isotopes such as 177Lu or 225Ac for therapeutic use – creating a true theranostic technology. They may play an important role in patient management in the future, and offer the potential for precision medicine for men with prostate cancer. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and has sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: ("LIGHTHOUSE," NCT04186819), in men with newly diagnosed prostate cancer, and "SPOTLIGHT," NCT04186845), in men with recurrent disease. Currently, rhPSMA compounds have not received regulatory approval.

On October 18, 2022 McKesson reported that it will play a major role in the upcoming 2022 Association for Value-Based Cancer Care (AVBCC) Summit, speaking on a wide range of topics that showcase their extensive knowledge of the changing healthcare landscape and oncology’s transformation to value-based care (Press release, McKesson, OCT 18, 2022, View Source [SID1234622144]). The Summit, to be held Oct. 19-21, 2022, in New York City, is an invitational forum that provides invaluable access to more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Staying ahead of the rapidly evolving landscape is challenging, and events like this greatly help, bringing together some of the best practices and ideas we can share to improve practice sustainability, clinical research and cancer care," said Lalan Wilfong, MD, vice president, Payer Relations & Practice Transformation, The US Oncology Network. "We are committed to being at the forefront of value-based care and are excited to have the opportunity to collaborate with other thought leaders at this important meeting."

Summit participants will gain insights from a diverse range of practitioners, pharmacists, payers, policymakers and other key stakeholders who are nationally recognized in their fields. Attendees will learn strategies on how to stay competitive in the ever-changing field of oncology, explore cutting-edge methodologies enabling value-based care that can rapidly be implemented, and gain access to timely and accurate information from reliable sources to empower good decision-making. It facilitates achievable change by providing a forum for payers, providers and the entire oncology team to network and evaluate value in terms of quality, cost and impact on patient care and outcomes.

McKesson is represented at the Summit by several of its experts, speaking on a diverse array of topics including value-based agreements, oncology drug trends, pathways and decision support models. Summit sessions featuring affiliated speakers as panelists are:

Headwinds and Tailwinds Ahead for Value-Based Agreements (Oct. 19, 8:30 a.m.-9:30 a.m.)
Lalan Wilfong, MD, vice president, Payer Relations & Practice Transformation, The US Oncology Network
Succeeding in Value-Based Payment Arrangements: ASCO (Free ASCO Whitepaper)’s Patient Centered Cancer Care Certification Pilot (Oct. 19, 10:30 a.m.-11:30 a.m.)
Matthew Skelton, MD, oncologist and physician champion for value-based care, Blue Ridge Cancer Care, a practice in The US Oncology Network
Legal and Regulatory Issues Surrounding Value-Based Agreements (Oct. 19, 2:15 p.m.-3:15 p.m.)
Ben Jones, vice president, Government Relations & Public Policy, The US Oncology Network
Lessons Learned from OCM That Should Be Incorporated into EOM and Future Cancer Care Models (Oct. 20, 9:45 a.m.-10:45 a.m.)
Marcus Neubauer, MD, chief medical officer, The US Oncology Network
How Long is the Last Mile? Real-World Evidence’s Vast Potential and Challenges in Oncology (Oct. 20, 3:15 p.m.-4 p.m.)
Viraj Narayanan, chief commercial officer, Ontada
Utilization of Pathways in Precision Medicine to Impact Patient Care (Oct. 21, 8 a.m.-9 a.m.)
Ira Zackon, MD, senior medical director, Ontada
The Impact Pathways Have on Outcomes and Value (Oct. 21, 10 a.m.-11 a.m.)
Lalan Wilfong, MD, vice president, Payer Relations & Practice Transformation, The US Oncology Network, and Marcus Neubauer, MD, chief medical officer, The US Oncology Network
Oncology Drug Supply Channels and the Move to Smart Networks and Supporting Value-Based Agreements (Oct. 21, 10 a.m.-11 a.m.)
Heather Morel, PhD, president, Provider Solutions, McKesson
Practice Transformation Through Value-Based Analytics (Oct. 21, 11 a.m.-12 p.m.)
Lalan Wilfong, MD, vice president, Payer Relations & Practice Transformation, The US Oncology Network
Payer and Provider Innovative Value-Based Agreement (Oct. 21, 2 p.m.-2:45 p.m.)
Rhonda Henschel, senior director, Payer Solutions, The US Oncology Network, and Jay Scott, director, Managed Care, Minnesota Oncology, a practice in The US Oncology Network
AI and ML Decision Support Models (Oct. 21, 2 p.m.-2:45 p.m.)
Ira Zackon, MD, senior medical director, Ontada
The live event is invitation-only, limiting the number of guests to adhere to COVID-19 safety guidelines; however, there will be a virtual simulcast of the entire Summit for those who cannot attend in person.